<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">121600</article-id><article-id pub-id-type="doi">10.23868/gc121600</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The adoption of expansion strategies of bone marrow derived mesenchymal stromal cells from patients with heart failure and co-morbidities</article-title><trans-title-group xml:lang="ru"><trans-title>Выбор стратегии экспансии мультипотентных мезенхимных стромальных клеток костного мозга, полученных от доноров с сердечной недостаточностью и коморбидностями</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dmitrieva</surname><given-names>R. I</given-names></name><name xml:lang="ru"><surname>Дмитриева</surname><given-names>Р. И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Klukina</surname><given-names>M. A</given-names></name><name xml:lang="ru"><surname>Клюкина</surname><given-names>М. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Minullina</surname><given-names>I. R</given-names></name><name xml:lang="ru"><surname>Минуллина</surname><given-names>И. Р</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Anisimov</surname><given-names>S. V</given-names></name><name xml:lang="ru"><surname>Анисимов</surname><given-names>С. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zaritskey</surname><given-names>A. Yu</given-names></name><name xml:lang="ru"><surname>Зарицкий</surname><given-names>А. Ю</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Insitute of Molecular Biology and Genetics of the Almazov Federal Heart, Blood and Endocrinology Centre, St. Petersburg</institution></aff><aff><institution xml:lang="ru">Институт молекулярной биологии и генетики Федерального Центра сердца, крови и эндокринологии им. В.А. Алмазова, Санкт-Петербург</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute of Haematology of the Almazov Federal Heart, Blood and Endocrinology Centre, St. Petersburg</institution></aff><aff><institution xml:lang="ru">Институт Гематологии, Федерального Центра сердца, крови и эндокринологии им. В.А. Алмазова, Санкт-Петербург</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2013</year></pub-date><volume>8</volume><issue>1</issue><issue-title xml:lang="en">VOL 8, NO1 (2013)</issue-title><issue-title xml:lang="ru">ТОМ 8, №1 (2013)</issue-title><fpage>36</fpage><lpage>42</lpage><history><date date-type="received" iso-8601-date="2023-01-11"><day>11</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Эко-Вектор</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/121600">https://genescells.ru/2313-1829/article/view/121600</self-uri><abstract xml:lang="en"><p>Autologous transplantation of bone marrow derived multipotent mesenchymal stromal cells is considered as a promising treatment for cardiovascular diseases including heart failure. The phenotype of patient with heart failure changed over the last two decades: the percentage of very old individuals, and number of comorbidities increased markedly. These factors could affect the functional properties of mesenchymal stromal cells intended for autologous transplantation. In this study for a first time the functional properties of cell samples from patients with heart failure and co-morbidities (obesity and diabetes mellitus) were investigated and the possibilities to compensate for the effects of patient factors on stromal cell properties by correcting ex vivo expansion strategies were studied. 10 healthy donors, 16 with isolated heart failure, 21 with comorbid obesity, 3 with diabetes and 9 with obesity and diabetes were enrolled. Cultures were evaluated in successive passages for immunophenotype, proliferative activity (population doubling time), frequency of colony-forming units, frequency of adipo- and osteo-progenitors at different seeding density under hypoxia/normoxia. The proliferation rate of mesenchymal stromal cells from patients with heart failure and co-morbidities decreased at early passages while seeded at 3000 cells/ cm2. The cultures with low proliferation rate demonstrated senescence-associated features and low frequency of clonogenic multipotent cells. At seeding density 100 cells/ cm2 cultures maintained high proliferation rate, hypoxia enhanced this effect even further up to 17—28 in vitro population doublings. Some of the donor-specific alterations in cell sample properties could be corrected by changing of culturing strategies.</p></abstract><trans-abstract xml:lang="ru"><p>Трансплантация аутогенных мультипотентных мезенхимных стромальных клеток (ММСК) костного мозга рассматривается в качестве нового перспективного подхода в лечении сердечно-сосудистых заболеваний, в том числе хронической сердечной недостаточности (ХСН). Кандидатами для такого лечения могут оказаться пожилые пациенты с широким спектром сопутствующих заболеваний, которые могут влиять на функциональные свойства клеточного образца — субстрата трансплантации. В данной работе впервые исследовано влияние ХСН, ожирения и сахарного диабета на свойства клеточного препарата, а также исследованы возможности снижения зависимости свойств клеточного материала от индивидуальных характеристик донора. ММСК были получены из образцов костного мозга 10 здоровых доноров, 16 пациентов с изолированной ХСН, 21 пациента с ХСН и ожирением, 3 пациентов с ХСН и сахарным диабетом, и 9 пациентов с ХСН, ожирением и диабетом. Свойства полученных образцов исследовали на последовательных пассажах при различной плотности посева в условиях гипоксии и нормоксии: иммунофенотип, пролиферативная активность, дифференцировочный потенциал. У пациентов с ХСН и коморбидностями пролиферативная активность клеток существенно снижалась по сравнению с полученными от здоровых доноров уже на ранних пассажах и сопровождалось развитием признаков репликативного старения, снижением доли клоногенных мульти-потентных клеток. При уменьшении плотности посева до 100 кл/см 2 наблюдалось существенное увеличение числа удвоений клеточной популяции при сохранении стабильной пролиферативной активности, а гипоксия дополнительно увеличивала продолжительность поддержания высокой пролиферативной активности образца без развития признаков репликативного старения. Показано, что изменение тактики in vitro экспансии существенно снижает влияние индивидуальных особенностей донора на функциональные свойства ММСК костного мозга.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>multipotent mesenchymal stromal cells</kwd><kwd>proliferation</kwd><kwd>differentiation</kwd><kwd>cell aging</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>мультипотентные мезенхимные стромальные клетки</kwd><kwd>пролиферация</kwd><kwd>дифференцировка</kwd><kwd>клеточное старение</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Shabbir A., Zisa D., Suzuki G. et al. Am heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. J. Physiol. Heart. Circ. Physiol. 2009; 296: H1888-97.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Trachtenberg B.,Velazquez R.N., Williams A.R. et al. Rationale and design of the transendocardial injection of autologous human cells [bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. American Heart Journal 2011; 161(3): 487—93.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kumar М.Р. Bone marrow-derived mesenchymal stem cells for treatment of heart failure: is it all paracrine actions and immunomodulation? Cardiovascular Medicine 2008; 9(2): 122-8.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Hatzistergos K.E., Quevedo H., Oskouei B.N. et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ. Res. 2010; 107: 913—22.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Miyahara Y., Nagaya N.,Kataoka М. et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nature Medicine 2006; 12: 459—65.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Quevedoa H.C., Hatzistergosa R.E., Oskouei B.N. et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. PNAS USA 2009; 106(33): 14022-7.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hare JM., Traverse J.H., Timothy D. et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 2009; 54(24): 2277-86.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Heldman A.W., Zambrano J.P., Hare JM. Cell therapy for heart disease: where are we in 2011? Am. Coll. Cardiol. 2011; 57: 466-8.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Segers V.FM., Richard T. Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008; 451: 937-42.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Angert D., Houser S.R. Stem cell therapy for heart failure. Curr. Treat. Opt. Cardiovas. Med. 2009; 11: 316-27.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Dominici М., Le Blanc K., Mueller I. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy 2006; 8: 315-27.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Giordano A., Galderisi U., Marino I.R. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J. Cell Physiol. 2007; 211: 27—35.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Preda M.B., Valen G. Evaluation of gene and cell-based therapies for cardiac regeneration. Curr. Stem Cell Res. Ther. 2013; Epub ahead of print.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Amado L.C., Saliaris A.P., Schuleri K.H. et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. PNAS USA 2005; 102: 11474—9.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Shabbir A., Zisa D., Leiker M. et al. Muscular dystrophy therapy by non-autologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation. Transplantation 2009; 87(9): 1275-82.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Tyndall A., Walker U.A., Cope A. et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK. Arthritis Res. Ther. 2007; 9: 301.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hare J.M., Traverse J.H., Henry T.D. et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 2009; 54: 2277-86.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wong C.Y., Sarwat I. Chaudhry S.I., Desai M.M. et al. Trends in comorbidity, disability, and polypharmacy in heart failure. Am. J. Med. 2011; 124: 136-43.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Stolzing A., Jones E., McGonagle D. et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mechanisms of Ageing and Development 2008; 129: 163-73.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Bork S., Pfister S., Witt H. et al., DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell 2010; 9(1): 54-63.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Pittenger M.F., Mackay A.M., Beck S.C. et al. Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science 1999; 284: 143-7.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Cristofalo V.J., Allen R.G., Pignolo R.J. et al. Relationship between donor age and the replicative lifespan of human cells in culture: A reevaluation. PNAS USA 1998; 95(18): 10614-9.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Mitchell J.B., Mcintosh K., Zvonic S. et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells 2006; 24: 376-85.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Bianco P., Robey, P.G. Skeletal stem cells. In: R.P. Lanza, editor. Handbook of adult and fetal stem cells. San Diego, CA: Academic Press, 2004: 415-24.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Wagner W., Horn P., Castoldi M. et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PloS ONE 2008; 3(5): e2213.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Bianco P., Robey P.G., Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008; 2(4): 313-9.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Fossett E., W. S. Khan W.S. Optimising human mesenchymal stem cell numbers for clinical application: a literature review. Stem Cells International 2012; Article iD 465259, 5 pages. Published online 2012 January 31.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Fossett E., Khan W.S., Longo U.G. et al. Effect of age and gender on cell proliferation and cell surface characterization of synovial fat pad derived mesenchymal stem cells. J. Orthop. Res. 2012; 30(7): 1013-8.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Tsai C.C., Chen Y.J., Yew T.L. et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011; 117(2): 459-69.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Both S.K., Van der Muijsenberg A.J., van Blitterswijk C.A. et al. A rapid and efficient method for expansion of human mesenchymal stem cells. Tissue Eng. 2007; 13: 3-9.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Colter D.C., Class R., DiGirolamo C.M. et al. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. PNAS USA 2000; 97: 3213.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Gregory C.A., Singh H., Perry,A.S. et al. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J. Biol. Chem. 2003; 278: 28067.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>De Boer J., Wang H.J., Van Blitterswijk C. Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng. 2004; 10: 393.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Valorani M.G., Montelatici E., Germani A. et al. Pre-culturing human adipose tissue mesenchymal stem cells under hypoxia increases their adipogenic and osteogenic differentiation potentials. Cell Prolif. 2012; 45; 225-38.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Жамбалова А.П., Гершович Ю.Г., Буравкова Л.Б. и др. Влияние пониженного содержания кислорода на дифференциров-ку мезенхимальных стромальных клеток костного мозга человека in vitro. Клеточная трансплантология и тканевая инженерия 2009; IV(3): 47-51.</mixed-citation></ref></ref-list></back></article>
